Skip to main content
I

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物第二届董事会2026年第四次会议决议公告
Regulatory Filings Classification · 1% confidence The document is a formal announcement by the company’s board of directors detailing the resolutions passed at its 2026 fourth meeting (e.g., approval of reports, profit distribution plan, incentive plans, and authorizations). It does not introduce a change in board composition or senior management (so not MANG), nor is it a financial report itself (10-K, IR, ER) or an investor presentation (IP), nor is it simply announcing a report (RPA). It is a regulatory corporate filing conveying board meeting outcomes that does not fit a more specific category, so it defaults to a general regulatory filing (RNS).
2026-04-14 Chinese
益方生物关于2022年限制性股票激励计划首次授予部分第三个归属期及预留授予部分（第二批）第二个归属期符合归属条件的公告
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory announcement by a listed company on the Shanghai Stock Exchange detailing the vesting conditions met and the number of restricted shares under its 2022 equity incentive plan that will be issued and registered. It is not an earnings release, proxy, board change, or management discussion. Instead, it announces a capital change via share issuance to employees under a restricted stock plan, matching the “Share Issue/Capital Change” category (Code: SHA).
2026-04-14 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司2025年度募集资金存放与实际使用情况的专项核查意见
Capital/Financing Update Classification · 1% confidence The document is titled as a sponsor’s “专项核查意见” (special inspection opinion) regarding the deposit and actual use of 2025 fundraising proceeds following the company’s IPO. It comprehensively details the fundraising amount, account storage, usage breakdown, cash management, project investment, and audit opinions. This is not a general annual or interim report, earnings release, or governance code, but a targeted compliance update on the proceeds from the equity issuance. The most fitting category is “Capital/Financing Update” (CAP), as it pertains to post-issuance use of raised capital.
2026-04-14 Chinese
益方生物2025年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 1% confidence The document is a standalone audit performance evaluation report (“2025年度会计师事务所履职情况评估报告”) detailing the auditor’s credentials, risk capacity, litigation history, resource allocation, audit plan, quality control, and information security processes. It is not an Annual Report or earnings release, nor an announcement of publication. It fits the definition of a detailed audit information report, so the correct category is Audit Report / Information (AR).
2026-04-14 Chinese
益方生物募集资金管理制度（2026年4月修订）
Governance Information Classification · 1% confidence The document is a detailed management policy (“募集资金管理制度”) issued by the company’s board that lays out internal rules, procedures, and governance practices for handling raised funds. It is not a shareholder meeting presentation, financial report, earnings release, or announcement, but rather a governance framework. This matches the definition of Governance Information (CGR).
2026-04-14 Chinese
益方生物2025年年度报告摘要
Interim / Quarterly Report Classification · 1% confidence The document is titled '益方生物科技（上海）股份有限公司2025年年度报告摘要' (InventisBio Co., Ltd. 2025 Annual Report Summary). It contains key financial highlights, business operations, and management discussion for the fiscal year 2025. Although it is a summary, it is a formal component of the annual reporting process for a publicly traded company on the Shanghai Stock Exchange (STAR Market). According to the classification rules, this falls under the 'Interim / Quarterly Report' (IR) category as it provides substantive financial data and analysis for a specific reporting period, or more accurately, it is the summary of the Annual Report. Given the provided categories, 'IR' is the most appropriate fit for a comprehensive financial report/summary of this nature. FY 2025
2026-04-14 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.